Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity

An anti-CD30 antibody-drug conjugate incorporating the antimitotic agent DM1 and a stable SMCC linker, anti-CD30-MCC-DM1, was generated as a new antitumor drug candidate for CD30-positive hematological malignancies. Here, the in vitro and in vivo pharmacologic activities of anti-CD30-MCC-DM1 (also k...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yijun, Yang, Tong, Cao, Xuemei, Zhang, Yifan, Zhao, Li, Li, Hua, Zhao, Teng, Xu, Jun, Zhang, Hengbin, Guo, Qingsong, Cai, Junli, Gao, Bei, Yu, Helin, Yin, Sicheng, Song, Ruiwen, Wu, Jingsong, Guan, Lingyu, Wu, Guanghao, Jin, Li, Su, Yong, Liu, Yanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748589/
https://www.ncbi.nlm.nih.gov/pubmed/31161871
http://dx.doi.org/10.1080/19420862.2019.1618674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748589/
https://www.ncbi.nlm.nih.gov/pubmed/31161871
http://dx.doi.org/10.1080/19420862.2019.1618674

Ejemplares similares